Pleural effusion aetiology, presentation, treatment and outcome in haematological diseases: a review.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
03 11 2021
03 11 2021
Historique:
received:
16
05
2021
accepted:
30
05
2021
entrez:
5
11
2021
pubmed:
6
11
2021
medline:
12
11
2021
Statut:
epublish
Résumé
Pleural effusions (PE) can complicate the course of hematologic disorders (HD) and may arise in the form of malignant PE or as a consequence of non-neoplastic complications. While a certain amount of data has been published regarding infectious and iatrogenic HD-associated PE (HPE), no comprehensive review regarding the other types of HPE has ever been conducted. To address this issue, we performed a systematic review of the literature regarding HPE, focusing on the clinical and chemical characteristics of PE, therapeutic approaches and ì outcomes at the one-year follow-up. We conducted our review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Overall, 283 manuscripts and 1216 cases were included. In summary, PE frequently signals an underlying HD, especially Hodgkin's lymphoma and IgG4-related disease; it mainly consists of exudate, although chylothorax is diagnosed in some cases. Although cytological examination has a discrete diagnostic yield, it is generally insufficient to render a definitive diagnosis; pleural biopsy remains an important diagnostic means in such cases. Invasive diagnostic procedures are not frequently performed because of an increased risk of haemorrhagic complications. The majority of PE are resolved by means of systemic therapy. When local treatments are attempted, the most frequently adopted procedures are evacuative thoracentesis and indwelling chest tube placement Conclusions: This review highlights the need for well-designed prospective studies comparing diagnostic means and therapeutic interventions for HPE to increase the quality of available data. (www.actabiomedica.it).
Sections du résumé
BACKGROUND AND AIM
Pleural effusions (PE) can complicate the course of hematologic disorders (HD) and may arise in the form of malignant PE or as a consequence of non-neoplastic complications. While a certain amount of data has been published regarding infectious and iatrogenic HD-associated PE (HPE), no comprehensive review regarding the other types of HPE has ever been conducted. To address this issue, we performed a systematic review of the literature regarding HPE, focusing on the clinical and chemical characteristics of PE, therapeutic approaches and ì outcomes at the one-year follow-up.
METHODS
We conducted our review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
RESULTS
Overall, 283 manuscripts and 1216 cases were included. In summary, PE frequently signals an underlying HD, especially Hodgkin's lymphoma and IgG4-related disease; it mainly consists of exudate, although chylothorax is diagnosed in some cases. Although cytological examination has a discrete diagnostic yield, it is generally insufficient to render a definitive diagnosis; pleural biopsy remains an important diagnostic means in such cases. Invasive diagnostic procedures are not frequently performed because of an increased risk of haemorrhagic complications. The majority of PE are resolved by means of systemic therapy. When local treatments are attempted, the most frequently adopted procedures are evacuative thoracentesis and indwelling chest tube placement Conclusions: This review highlights the need for well-designed prospective studies comparing diagnostic means and therapeutic interventions for HPE to increase the quality of available data. (www.actabiomedica.it).
Identifiants
pubmed: 34738567
doi: 10.23750/abm.v92i5.11794
pmc: PMC8689299
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2021268Références
Eur J Radiol. 2010 Nov;76(2):228-38
pubmed: 19581062
Ann Intern Med. 1966 Feb;64(2):328-40
pubmed: 5216294
Thorax. 2014 Dec;69(12):1098-104
pubmed: 25100651
J Thorac Dis. 2016 Jul;8(7):E486-94
pubmed: 27499981
Pediatr Hematol Oncol. 2000 Dec;17(8):695-9
pubmed: 11127402
Clin Chest Med. 2017 Jun;38(2):317-331
pubmed: 28477642
Chest. 2005 Jun;127(6):2101-5
pubmed: 15947326
Cancer. 1973 Apr;31(4):848-53
pubmed: 4574663
Eur Rev Med Pharmacol Sci. 2007 Nov-Dec;11(6):373-4
pubmed: 18306905
J Bronchology Interv Pulmonol. 2016 Jan;23(1):79-82
pubmed: 26496088
Br J Haematol. 2007 Nov;139(4):621-2
pubmed: 17979947
Br J Dis Chest. 1981 Jan;75(1):22-30
pubmed: 7259964
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Am J Surg Pathol. 2010 Dec;34(12):1812-9
pubmed: 21107087
Am J Surg Pathol. 2009 Oct;33(10):1450-62
pubmed: 19623032
Eur Respir J. 2018 Jul 27;52(1):
pubmed: 30054348
Med Pediatr Oncol. 1994;23(2):153-7
pubmed: 8202041
Ann Hematol. 2001 Mar;80(3):183-6
pubmed: 11324648
Am J Surg Pathol. 2008 Nov;32(11):1620-6
pubmed: 18753944
Med Pediatr Oncol. 2000 Apr;34(4):274-5
pubmed: 10742069
Thorax. 1979 Feb;34(1):29-32
pubmed: 441997
Leuk Lymphoma. 2002 Nov;43(11):2083-92
pubmed: 12533032
Acta Cytol. 1987 Mar-Apr;31(2):119-24
pubmed: 3548191
Cancer. 2003 Nov 1;98(9):1912-7
pubmed: 14584074
Acta Haematol. 1998;99(1):34-7
pubmed: 9490564
Leuk Lymphoma. 2012 Jan;53(1):156-7
pubmed: 21740301
Gut. 1992 Dec;33(12):1621-5
pubmed: 1487163
J Coll Physicians Surg Pak. 2020 Nov;30(11):1220-1222
pubmed: 33222745
Leuk Lymphoma. 1996 Jan;20(3-4):229-37
pubmed: 8624461
J Coll Physicians Surg Pak. 2003 Feb;13(2):108-10
pubmed: 12685957
Med Clin (Barc). 1991 Feb 16;96(6):236
pubmed: 2041391
Intern Med. 2004 Mar;43(3):236-42
pubmed: 15098608
Respir Med. 1999 May;93(5):338-41
pubmed: 10464900
Ann Am Thorac Soc. 2017 Jun;14(6):976-985
pubmed: 28326798
Acta Cytol. 1998 Sep-Oct;42(5):1116-20
pubmed: 9755667
Crit Ultrasound J. 2018 Aug 1;10(1):18
pubmed: 30066098
BMJ Case Rep. 2015 Aug 17;2015:
pubmed: 26282457
Am J Hematol. 2010 Sep;85(9):711-2
pubmed: 20063279
Ann Thorac Surg. 2006 Jun;81(6):2037-43
pubmed: 16731126
Case Rep Oncol. 2020 Jul 30;13(2):929-934
pubmed: 32884542
Thorax. 2010 Aug;65 Suppl 2:ii61-76
pubmed: 20696688
Leuk Lymphoma. 1993 Aug;10(6):507-10
pubmed: 8401188
Medicine (Baltimore). 2020 Oct 30;99(44):e23030
pubmed: 33126392
Arch Intern Med. 1978 May;138(5):727-30
pubmed: 646535
Leuk Lymphoma. 2013 Feb;54(2):329-35
pubmed: 22812422
Ann Oncol. 1995 Jul;6(6):603-7
pubmed: 8573541
South Med J. 1994 Nov;87(11):1183-5
pubmed: 7973913
Mayo Clin Proc. 1995 Dec;70(12):1161-4
pubmed: 7490917
Rev Clin Esp (Barc). 2018 Mar;218(2):89-97
pubmed: 29197468
Hematology Am Soc Hematol Educ Program. 2009;:80-6
pubmed: 20008185
Curr Opin Pulm Med. 2013 Jul;19(4):368-73
pubmed: 23719295
Chest. 1994 Feb;105(2):622-4
pubmed: 8306782
Cancer. 1998 Oct 15;83(8):1607-11
pubmed: 9781955
Chest. 1993 Mar;103(3):974-5
pubmed: 8449115
East Afr Med J. 2004 Apr;81(4):215-7
pubmed: 15884290
Am J Surg Pathol. 2009 Dec;33(12):1886-93
pubmed: 19898222
Lancet. 1976 Aug 21;2(7982):414-5
pubmed: 73868
Leuk Lymphoma. 1995 Jul;18(3-4):365-6
pubmed: 8535208
Eur Respir J. 2012 Jan;39(1):180-6
pubmed: 21719489
Arch Bronconeumol. 2014 Aug;50(8):371-2
pubmed: 24698395